GILD vs. BMY
Compare and contrast key facts about Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GILD or BMY.
Correlation
The correlation between GILD and BMY is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GILD vs. BMY - Performance Comparison
Loading data...
Key characteristics
GILD:
2.11
BMY:
0.36
GILD:
3.01
BMY:
0.70
GILD:
1.38
BMY:
1.08
GILD:
1.92
BMY:
0.20
GILD:
10.43
BMY:
1.13
GILD:
5.49%
BMY:
8.62%
GILD:
27.11%
BMY:
31.53%
GILD:
-70.82%
BMY:
-70.62%
GILD:
-12.09%
BMY:
-35.93%
Fundamentals
GILD:
$124.92B
BMY:
$95.14B
GILD:
$4.86
BMY:
$2.73
GILD:
20.65
BMY:
17.12
GILD:
0.21
BMY:
2.26
GILD:
4.35
BMY:
2.00
GILD:
6.52
BMY:
5.36
GILD:
$28.73B
BMY:
$47.64B
GILD:
$23.07B
BMY:
$31.43B
GILD:
$9.89B
BMY:
$16.18B
Returns By Period
In the year-to-date period, GILD achieves a 11.75% return, which is significantly higher than BMY's -15.53% return. Over the past 10 years, GILD has outperformed BMY with an annualized return of 2.72%, while BMY has yielded a comparatively lower -0.58% annualized return.
GILD
11.75%
-2.27%
17.75%
56.72%
10.49%
2.72%
BMY
-15.53%
-5.29%
-15.02%
11.19%
-2.62%
-0.58%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GILD vs. BMY — Risk-Adjusted Performance Rank
GILD
BMY
GILD vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
GILD vs. BMY - Dividend Comparison
GILD's dividend yield for the trailing twelve months is around 3.02%, less than BMY's 5.22% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GILD Gilead Sciences, Inc. | 3.02% | 3.33% | 3.70% | 3.40% | 3.91% | 4.67% | 3.88% | 3.65% | 2.90% | 2.57% | 1.27% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.22% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
GILD vs. BMY - Drawdown Comparison
The maximum GILD drawdown since its inception was -70.82%, roughly equal to the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for GILD and BMY. For additional features, visit the drawdowns tool.
Loading data...
Volatility
GILD vs. BMY - Volatility Comparison
Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY) have volatilities of 11.99% and 11.57%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
GILD vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GILD vs. BMY - Profitability Comparison
GILD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a gross profit of 5.71B and revenue of 6.67B. Therefore, the gross margin over that period was 85.6%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
GILD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported an operating income of 3.15B and revenue of 6.67B, resulting in an operating margin of 47.2%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
GILD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Gilead Sciences, Inc. reported a net income of 1.32B and revenue of 6.67B, resulting in a net margin of 19.7%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.